Treatment paradigms in advanced non-small-cell lung cancer

Caroline E. Mccoach, Karen Kelly

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.

Original languageEnglish (US)
Pages (from-to)629-639
Number of pages11
JournalClinical Advances in Hematology and Oncology
Volume11
Issue number10
StatePublished - Oct 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Therapeutics
Standard of Care
Lung Neoplasms
Survival Rate
Research
Neoplasms

Keywords

  • Chemotherapy
  • Maintenance therapy
  • Molecularly targeted therapy
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Treatment paradigms in advanced non-small-cell lung cancer. / Mccoach, Caroline E.; Kelly, Karen.

In: Clinical Advances in Hematology and Oncology, Vol. 11, No. 10, 10.2013, p. 629-639.

Research output: Contribution to journalArticle

@article{3735c2379a4e402d9f8a9ee2d63df484,
title = "Treatment paradigms in advanced non-small-cell lung cancer",
abstract = "Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.",
keywords = "Chemotherapy, Maintenance therapy, Molecularly targeted therapy, Non-small-cell lung cancer",
author = "Mccoach, {Caroline E.} and Karen Kelly",
year = "2013",
month = "10",
language = "English (US)",
volume = "11",
pages = "629--639",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "10",

}

TY - JOUR

T1 - Treatment paradigms in advanced non-small-cell lung cancer

AU - Mccoach, Caroline E.

AU - Kelly, Karen

PY - 2013/10

Y1 - 2013/10

N2 - Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.

AB - Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.

KW - Chemotherapy

KW - Maintenance therapy

KW - Molecularly targeted therapy

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84887101376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887101376&partnerID=8YFLogxK

M3 - Article

C2 - 24518373

AN - SCOPUS:84887101376

VL - 11

SP - 629

EP - 639

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 10

ER -